Gastrointestinal Conditions: Inflammatory Bowel Disease

Area of Science:

• Gastroenterology and Immunology
• Microbiome Research
• Host-Pathogen Interactions

Background:

• Inflammatory bowel diseases (IBDs) are chronic conditions characterized by immune dysregulation in response to gut microbiota.
• IBDs affect 1.3% of the US population, encompassing Crohn disease (CD), ulcerative colitis (UC), and microscopic colitis.
• Symptoms range from gastrointestinal distress (diarrhea, pain) to systemic effects (fatigue, fever) and extraintestinal manifestations (joints, skin, eyes).

Purpose of the Study:

• To provide an overview of Inflammatory Bowel Diseases (IBD).
• To discuss the etiology, symptoms, diagnosis, and treatment of IBD.
• To highlight recent advancements in IBD management.

Main Methods:

• Diagnosis involves colonoscopy with biopsy for UC and microscopic colitis.
• Crohn disease diagnosis often requires ileocolonoscopy and potentially esophagogastroduodenoscopy.
• Review of traditional and modern therapeutic approaches.

Main Results:

• Traditional therapies include mesalamine (UC), thiopurines/methotrexate (CD), and budesonide (microscopic colitis).
• Biologic drugs targeting tumor necrosis factor alpha have significantly advanced IBD care.
• Surgery can be curative for UC, while CD management involves surgery for complications or refractory cases.

Conclusions:

• IBD management has been revolutionized by biologic therapies.
• Treatment strategies are tailored to specific IBD types (CD, UC, microscopic colitis).
• Ongoing research continues to refine therapeutic options for IBD.